Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs

Cigna's Evernorth has reached agreements with Eli Lilly and Novo Nordisk to lower the cost of GLP-1 weight loss drugs like Wegovy and Zepbound for employers and their workers, potentially reducing employer costs by up to 20% while capping member out-of-pocket expenses at $200 per month. This move aims to expand coverage among employers hesitant due to high costs, complementing CVS Caremark's recent deal favoring Wegovy and preceding Medicare's forthcoming negotiated discounts for these drugs in 2027, which analysts believe will further drive down net prices across the market.

Analysis

Cigna's pharmacy benefits unit, Evernorth, has brokered agreements with Eli Lilly and Novo Nordisk designed to significantly lower the cost of GLP-1 weight loss drugs, Wegovy and Zepbound, aiming to expand coverage among employers, of whom only half currently include these high-cost medications in their plans. The new program, commencing July 1, will offer reduced prices to plan sponsors, potentially cutting their costs by up to 20% for those already covering the drugs, and notably caps member out-of-pocket expenses at $200 per month – substantially less than uninsured cash prices ($1,100-$1,350 list). This initiative, which also simplifies pre-authorization, follows a period where net prices for these drugs already reflect discounts of 30-50% from list (e.g., Wegovy's $616 net vs. $1,350 list) and occurs amidst a dynamic PBM landscape, evidenced by CVS Caremark's recent move to favor Wegovy. The agreements are particularly timely as the market anticipates further downward price pressure from Medicare negotiations under the Inflation Reduction Act, which will directly impact Novo Nordisk's GLP-1s by 2027 and subsequently influence Eli Lilly's pricing strategy to remain competitive in the Medicare market, likely leading to broader net price reductions.

Key Decisions for Investors

• Investors should assess the potential for Cigna's (CI) Evernorth to gain market share and enhance client retention through its new, more affordable GLP-1 drug program, which directly addresses employer cost concerns.
• For Eli Lilly (LLY) and Novo Nordisk (NVO), the key consideration is whether increased patient volume from these PBM agreements will sufficiently offset the lower net prices per unit, especially given the intensifying price competition and the looming impact of Medicare price negotiations post-2027.
• Monitor closely the formulary positioning and competitive responses among major PBMs, including CVS Health (CVS), as their strategies will be critical determinants of market share and profitability for GLP-1 manufacturers in the evolving landscape.